enGene Therapeutics
ENGN
36 hedge funds and large institutions have $147M invested in enGene Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
16% more funds holding
Funds holding: 31 → 36 (+5)
1.24% less ownership
Funds ownership: 80.31% → 79.07% (-1.2%)
20% less capital invested
Capital invested by funds: $183M → $147M (-$36.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.68M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$289K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$152K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$86.5K |
| 5 |
Millennium Management
New York
|
+$48.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.14M |
| 2 |
O
OrbiMed
New York
|
-$802K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$514K |
| 4 |
Morgan Stanley
New York
|
-$314K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$282K |
ENGN Hedge Fund Activity: Q2 2025 in Review
36 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q2 2025, worth a combined $147M — down 20% from $183M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ENGN positions and 3 closed out — a net gain of 5 holders — while 4 added to existing stakes and 9 trimmed.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $1.68M. The largest seller was Adage Capital Partners, cutting an estimated $2.14M.
- 36 institutional investors held enGene Therapeutics (ENGN) as of Q2 2025, up from 31 in Q1 2025.
- Funds reported $147M of enGene Therapeutics stock for Q2 2025, down 20% quarter-over-quarter.
- 8 funds opened new enGene Therapeutics positions in Q2 2025 and 3 closed out, a net change of +5 holders.
- The largest enGene Therapeutics buyer in Q2 2025 was Blue Owl Capital Holdings, an estimated $1.68M added.
- The largest enGene Therapeutics seller in Q2 2025 was Adage Capital Partners, an estimated $2.14M sold.
Based on aggregated 13F filings for Q2 2025.